Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy.
about
An evidence-based algorithm for the treatment of neuropathic painThe topical 5% lidocaine medicated plaster in localized neuropathic pain: a reappraisal of the clinical evidenceThe 5% Lidocaine-Medicated Plaster: Its Inclusion in International Treatment Guidelines for Treating Localized Neuropathic Pain, and Clinical Evidence Supporting its UseEnigma of painful diabetic neuropathy: can we use the basic science, research outcomes and real-world data to help improve patient care and outcomes?Treatment of diabetic sensory polyneuropathy.Diabetic neuropathy: mechanisms to managementTreating Diabetic Neuropathy: Present Strategies and Emerging Solutions.Efficacy of gabapentin in the improvement of pruritus and quality of life of patients with notalgia paresthetica.Treatment of painful diabetic neuropathyBurning through the pain: treatments for diabetic neuropathy.Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment.Outcome predictors for treatment success with 5% lidocaine medicated plaster in low back pain with neuropathic components and neuropathic pain after surgical and nonsurgical traumaDiabetic neuropathy: new strategies for treatment.Topical lidocaine patch 5% for acute postoperative pain control.Update on the management of diabetic polyneuropathies.Pharmacological treatment of diabetic peripheral neuropathy.Treatment of localized post-traumatic neuropathic pain in scars with 5% lidocaine medicated plaster.Can treatment success with 5% lidocaine medicated plaster be predicted in cancer pain with neuropathic components or trigeminal neuropathic pain?Safety profile of treatment in diabetic peripheral neuropathic pain.Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review.Novel Treatment of Radicular Pain With a Multi-Mechanistic Combination Topical Agent: A Case Series and Literature ReviewVoltage-gated sodium channel blockers for the treatment of neuropathic pain.Use of lidocaine patches for neuropathic pain in a comprehensive cancer centre.Pain associated with diabetic peripheral neuropathy: a review of available treatmentsPharmacological treatment of diabetic neuropathic pain.Clinical Approach to the Treatment of Painful Diabetic Neuropathy.Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature.Management of chronic noncancer pain in depressed patients.Diabetic neuropathy and oxidative stress: therapeutic perspectives.Treatment of painful diabetic peripheral neuropathy.Skin Matters: A Review of Topical Treatments for Chronic Pain. Part Two: Treatments and Applications.Understanding and treating painful diabetic neuropathy: time for a paradigm shift.Topical Treatments for Localized Neuropathic Pain.Lidocaine Skin Patch (Lidopat® 5%) Is Effective in the Treatment of Traumatic Rib Fractures: A Prospective Double-Blinded and Vehicle-Controlled Study.Is lidocaine patch as effective as intravenous lidocaine in pain and illus reduction after laparoscopic colorectal surgery? A randomized clinical trialAntihyperalgesic efficacy of 5% lidocaine medicated plaster in capsaicin and sunburn pain models--two randomized, double-blinded, placebo-controlled crossover trials in healthy volunteers.Pharmacokinetics of a lidocaine patch 5% in dogs.Management of chronic neuropathic pain with single and compounded topical analgesics.Guidelines for the diagnosis and management of neuropathic pain: consensus of a group of Latin American experts.
P2860
Q24680820-847E570E-AE99-4889-83A1-2E9BA3A911E2Q26765263-BD3CCEEB-CA9F-4468-80F1-6D04A94D5E0BQ28069535-17E3B63D-1ABE-4F32-BEE0-D52391C63ED7Q31043237-D0A81BB0-9F79-4306-9074-3F87A6F58993Q33393882-F41238FC-B8EA-4AC2-8957-725675FE599AQ33554384-53D49944-9F4A-4B28-8A41-F3599AC83278Q33583006-9B9C1166-7EBE-46CA-B56E-C9E47F26D6F2Q34104804-09F7EBF0-CE46-451E-8FA2-64B6626DDA4AQ34456265-59684E7D-5AAF-4ECC-8049-AA6C1DAA536DQ34485306-8C2FDD1C-95A3-4458-9EDE-33FE21D49DC0Q34595383-5342E2D1-B768-498B-80C8-1546EFBCD254Q34623739-C09B18B7-194A-4532-98F5-B5BFC4AF159BQ34641965-E06206BA-66D3-4C88-A5F7-4480802FE7F8Q34710016-967DEB47-F548-41C8-B973-2A2D53828CA9Q35178801-694BAC94-BE08-483A-87E6-05B6CF5DBF61Q35669997-8E790A08-63C6-42CC-A1D4-1667EDD51D85Q36160742-0B3D93B6-5074-4E36-91E5-EF0465FDB1E5Q36758278-F12EC30C-52A0-4AA5-B6BD-A8FA142B0917Q36917013-24F64A91-4266-42DF-876A-88BFA50F766FQ36917017-0576297F-3E27-43C0-856A-72F85C2361A8Q36950068-D7694297-AFD2-4D2A-8534-AD33DC24F22DQ36998857-981215F7-487B-4031-ADA4-7414ED34F8D5Q37425431-3D1B0800-3ECC-4938-8323-CC3E65AFB724Q37596278-0A41B962-9ECA-49A5-B6C7-281B77021C44Q37858519-756A6673-A73D-4EE7-A585-C028095DB2F3Q37895130-5D4C5774-18BE-40D3-8EDF-95E401A3B6ACQ37907386-01EDC16F-36A6-4596-A0A0-DB9CC56CB2B1Q37929505-7EE799D3-FBF0-4E8B-B523-9BF2F3BDBDB5Q38112117-C924C3FD-4B05-4DF7-A7D9-69CA0D2E6C01Q38329620-75DAB248-A211-4E6C-91A3-9B932411C182Q38335767-2BE65DFD-60D4-431D-92EE-B7B13C6A2785Q38394422-D7AD1177-A632-4E79-9612-74A279CE576BQ39167455-0A2D0523-6206-43DE-8271-524F242A3583Q39181135-79987887-C5FE-49A2-9D38-6232B1296CCEQ41055639-E2589020-205E-4A87-8597-7DF6233D999CQ48246227-428399F3-DA6D-40F6-8251-2496269C4DAFQ48733744-247ACF6E-42F7-4480-8776-176D423E4746Q50072130-1E060AED-54B2-4C2A-B5F0-A466C648E408Q50600462-8853EB70-B8B3-4DCC-9BA1-B386B0C15A1C
P2860
Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Effectiveness, tolerability, a ...... ch in diabetic polyneuropathy.
@en
Effectiveness, tolerability, a ...... ch in diabetic polyneuropathy.
@nl
type
label
Effectiveness, tolerability, a ...... ch in diabetic polyneuropathy.
@en
Effectiveness, tolerability, a ...... ch in diabetic polyneuropathy.
@nl
prefLabel
Effectiveness, tolerability, a ...... ch in diabetic polyneuropathy.
@en
Effectiveness, tolerability, a ...... ch in diabetic polyneuropathy.
@nl
P2093
P1433
P1476
Effectiveness, tolerability, a ...... ch in diabetic polyneuropathy.
@en
P2093
David N Herrmann
Janet Pennella-Vaughan
Peter A Lodewick
Richard L Barbano
Robert H Dworkin
Stephanie Hart-Gouleau
P304
P356
10.1001/ARCHNEUR.61.6.914
P577
2004-06-01T00:00:00Z